| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 136.812 | 155.689 | 212.119 | 334.060 | 406.036 | 529.846 | 483.353 | 297.310 | 285.156 | 239.571 |
| Total Income - EUR | 136.909 | 159.484 | 228.568 | 372.803 | 440.398 | 530.479 | 485.196 | 329.159 | 299.509 | 246.269 |
| Total Expenses - EUR | 133.497 | 162.599 | 230.352 | 351.945 | 459.113 | 503.511 | 465.311 | 311.949 | 307.843 | 291.382 |
| Gross Profit/Loss - EUR | 3.412 | -3.115 | -1.784 | 20.858 | -18.715 | 26.968 | 19.885 | 17.210 | -8.334 | -45.112 |
| Net Profit/Loss - EUR | 3.412 | -3.115 | -5.382 | 18.023 | -24.105 | 22.045 | 15.034 | 13.918 | -11.329 | -47.316 |
| Employees | 5 | 5 | 6 | 7 | 9 | 9 | 0 | 7 | 7 | 6 |
Check the financial reports for the company - Byacrys Sanofarm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 11.945 | 13.501 | 16.118 | 40.343 | 38.506 | 71.453 | 56.919 | 65.496 | 44.297 | 44.123 |
| Current Assets | 85.012 | 92.823 | 101.922 | 110.071 | 108.040 | 139.163 | 160.505 | 137.448 | 94.429 | 79.861 |
| Inventories | 75.872 | 88.870 | 92.356 | 93.210 | 96.945 | 120.855 | 142.905 | 123.989 | 83.644 | 69.179 |
| Receivables | 3.594 | 1.933 | 7.341 | 8.244 | 9.385 | 15.629 | 15.853 | 12.003 | 9.004 | 9.895 |
| Cash | 5.546 | 2.020 | 2.225 | 8.617 | 1.710 | 2.679 | 1.747 | 1.456 | 1.781 | 788 |
| Shareholders Funds | -43.078 | -45.754 | -50.361 | -30.060 | -54.910 | -31.824 | -16.085 | -2.216 | -13.539 | -60.779 |
| Social Capital | 67 | 67 | 66 | 64 | 63 | 62 | 61 | 61 | 61 | 60 |
| Debts | 140.035 | 152.078 | 168.368 | 180.441 | 201.424 | 242.408 | 233.478 | 205.129 | 152.234 | 184.733 |
| Income in Advance | 0 | 0 | 33 | 33 | 32 | 32 | 31 | 31 | 31 | 31 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Byacrys Sanofarm S.r.l.